Oklahoma House Bill HB1168

Oklahoma 2026 Regular Session

• Introduced: 2/3/25
• Refer: 2/4/25
• Report Pass: 3/6/25
• Engrossed: 3/26/25
• Refer: 4/1/25
• Report Pass: 4/21/25
• Enrolled: 4/30/26
• Passed: 5/6/26

Caption

Abortion-inducing drugs; terms; trafficking; felony; exceptions; effective date.

Summary

HB1168 creates a new offense in Oklahoma law for trafficking in abortion-inducing drugs. The bill defines key terms such as “abortion,” “abortion-inducing drug,” “preventive contraception,” “trafficking,” and “unborn child,” and it specifically identifies drugs such as misoprostol and methotrexate when they are prescribed with the intent to induce an abortion. It also clarifies that the definition does not reach drugs used for other medical purposes, including treatment of ectopic pregnancy or miscarriage, or drugs that may have abortion-related effects when prescribed for unrelated medical indications. Under the bill, a person who knows or has reason to know that another person intends to use an abortion-inducing drug to cause an unlawful abortion commits trafficking if they deliver the drug or possess it with intent to deliver it. A conviction is a felony punishable by up to a $100,000 fine, up to 10 years in prison, or both. The bill includes exceptions for pharmacists and lawful manufacturers or distributors acting in the ordinary course of business, and it expressly states that lawful preventive contraception is not prohibited when used according to manufacturer instructions.

Impact

HB1168 adds a new criminal statute to Title 63 of the Oklahoma Statutes, expanding state regulation of abortion-related conduct beyond the procedure itself to the distribution and delivery of abortion-inducing medications. It creates felony liability for trafficking in such drugs when done with knowledge or reason to know of an unlawful abortion intent, while preserving exceptions for lawful medical and pharmaceutical activity and for contraception. The measure is likely to affect patients, prescribers, pharmacists, distributors, and others involved in medication access, especially where abortion medication is involved.

Sentiment

The bill appears to have received generally favorable support from legislative majorities, advancing through both chambers with clear margins. It passed House committees, the House floor, and the Senate Health & Human Services Committee, and it ultimately passed the Senate 37-10. The recorded debate transcript is brief, but the final vote totals indicate substantial support alongside a meaningful minority of opposition.

Contention

The main point of contention is the bill’s criminalization of the delivery or possession-for-delivery of abortion-inducing drugs when the actor knows or should know the recipient intends an unlawful abortion. Opponents likely objected to the expansion of criminal penalties and the potential chilling effect on medication access, while supporters likely viewed the measure as a tool to restrict abortion access through drug distribution. The bill attempts to address some concerns by carving out lawful pharmacy and manufacturer activity and by exempting preventive contraception and non-abortion medical uses of drugs such as treatment for ectopic pregnancy or miscarriage.